Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autor principal: | Flora, Sanzida Alam |
---|---|
Outros Autores: | Azam, Faruque |
Formato: | Thesis |
Idioma: | English |
Publicado em: |
Brac University
2024
|
Assuntos: | |
Acesso em linha: | http://hdl.handle.net/10361/23693 |
Registos relacionados
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
Por: Khan, Muidul Hasan
Publicado em: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
Por: Paul, Pulock
Publicado em: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
Por: Rahman, Tasnim
Publicado em: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
Por: Sorno, Rubina Haque
Publicado em: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
Por: Hoque, Ismoth Ara
Publicado em: (2024)